



- **433** Implementation of Health Initiatives During a Cease-Fire — Sudan, 1995
- **436** Mercury Exposure in a Residential Community Florida, 1994
- 443 Unexplained Illness Among Persian Gulf War Veterans in an Air National Guard Unit: Preliminary Report — August 1990–March 1995

Implementation of Health Initiatives During a Cease-Fire — Sudan, 1995

MORBIDITY AND MORTALITY WEEKLY REPORT

In 1994, Sudan (1994 population: 27 million) reported to the World Health Organization (WHO) one third of the global total of cases of dracunculiasis (i.e., Guinea worm disease), which is targeted for eradication by the end of 1995 (*1,2*). On March 27, 1995, the government of Sudan announced a cease-fire of 2 months' duration in the 12-yearold civil war in the southern part of the country—both sides agreed to the cease-fire primarily to permit acceleration of efforts to eradicate dracunculiasis and to promote treatment of other health problems including onchocerciasis (i.e., river blindness), administration of childhood vaccines, and distribution of vitamin A. This report summarizes the status of dracunculiasis and onchocerciasis in Sudan and provisional information on activities undertaken by the government of Sudan and other organizations during the cease-fire.

In 1994, the national Guinea Worm Eradication Program in Sudan reported to WHO a total of 780 villages with endemic drancunculiasis and 53,271 cases. The states with the highest prevalence of disease were Upper Nile, Bahr Al-Jabal, Eastern Equatoria, Western Bahr Al-Ghazal, and Northern Bahr Al-Gazal states (Figure 1). As of 1995, the prevalence of onchocerciasis in Sudan was estimated to be 620,000. Southern Sudan also includes the most highly endemic foci for blinding onchocerciasis; the main endemic foci are located in Western Equatoria, Northern Bahr Al-Ghazal, and Western Bahr Al-Ghazal States (Figure 2).

Immediately after the cease-fire was announced, the Carter Center and CDC began providing technical assistance to complement preexisting activities conducted by the United Nations Children's Fund (UNICEF), bilateral donors, and nongovernmental organizations. During the cease-fire, health workers from several organizations (including the Sudan Guinea Worm Eradication Program, the onchocerciasis and vaccination programs, and nongovernmental organizations), in collaboration with UNICEF's Operation Lifeline Sudan, trained approximately 1265 additional community health volunteers and deployed about 30 mobile teams of health workers. On April 27, health leaders from both sides met in Juba, Sudan, to exchange information, including maps showing the location of villages with endemic drancunculiasis to help ensure maximum coverage for investigation and interventions. Accelerated interventions began in late April.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES / Public Health Service

Sudan — Continued



FIGURE 1. Number of cases of dracunculiasis, by state — Sudan Guinea Worm Eradication Program, 1994

From late April through June 13, a total of 2028 villages were visited, including at least 651 villages in which dracunculiasis was first documented during the visit. Health workers identified 8922 new cases of dracunculiasis and distributed 87,703 cloth filters to households in villages with endemic disease. Through June 13, a provisional total of 9454 cases of dracunculiasis had been reported during 1995, including the cases newly identified during the cease-fire. In comparison, during January–May 1994, 15,798 cases were reported.

During the same period, mass oral treatment for onchocerciasis with ivermectin was initiated for the first time in many of the areas in the country with the highest prevalence of disease. Treatment was administered to a total of 25,499 persons from 84 villages in parts of Bahr Al-Ghazal and Equatoria zones, in which prevalences in 28 villages exceeded 40%, and to most eligible persons in the area around Raga, Western Bahr Al-Ghazal state. Assessments are continuing in other areas of the two zones with suspected endemic disease.

As of June 13, at least 30,865 children had received oral poliovirus vaccine, 35,996 were vaccinated against measles, and 19,204 had received bacille Calmette-Guérin (BCG) vaccination. In addition, 29,349 children had received vitamin A, and oral rehydration treatment had been administered to at least 5475 children with diarrhea. Health workers also had conducted health-education sessions to promote prevention

Sudan — Continued



FIGURE 2. Areas of Sudan where onchocerciasis (river blindness) is endemic — Sudan, 1995

of dracunculiasis, onchocerciasis, and diarrhea and to promote vaccination of children.

Reported by: Federal Ministry of Health, Khartoum, Sudan. Global 2000, Inc, The Carter Center; Task Force for Child Survival and Development; Mectizan Donation Program, Atlanta. World Health Organization Collaborating Center for Research, Training, and Eradication of Dracunculiasis, Div of Parasitic Diseases, National Center for Infectious Diseases; International Health Program Office; National Immunization Program, CDC.

Editorial Note: The cease-fire in Sudan permitted rapid development and implementation of activities to address dracunculiasis and other priority health problems. Interventions against dracunculiasis and onchocerciasis were expanded substantially from earlier levels and should accelerate the control of these diseases in Sudan and aid the global eradication effort. In 1994, control measures for dracunculiasis had been provided to approximately 50% of the villages with known endemic disease, and distribution of ivermectin to treat onchocerciasis in the southern part of the country had been restricted to only a limited number of clinics.

Because of this "Guinea worm cease-fire" in Sudan, the global campaign to eradicate dracunculiasis now encompasses all countries with endemic disease. In addition, this cease-fire is an unprecedented opportunity for Sudan to intensify efforts to eradicate poliomyelitis and to control onchocerciasis, measles, and vitamin A deficiency.

Sudan — Continued

Efforts to address health problems during negotiated periods of tranquility in civil and military strife have been conducted previously in Lebanon, El Salvador, Sudan, and other countries; however, the duration of these efforts has been substantially shorter than the current program in Sudan. On May 25, the government of Sudan and opposing forces announced their willingness to extend the cease-fire for an additional 2 months through late July to enable continued disease-control efforts.

References

- 1. World Health Organization. Dracunculiasis eradication: update—Sudan. Wkly Epidemiol Rec 1995;70:48–50.
- 2. World Health Organization. Dracunculiasis: global surveillance summary, 1994. Wkly Epidemiol Rec 1995;70:125–32.

Mercury Exposure in a Residential Community — Florida, 1994

Residential exposure to elemental mercury typically involves small amounts (e.g., the approximately 0.3 mL in a thermometer). During August 1994, five children residing in a neighborhood in Palm Beach County, Florida, found 5 pints of elemental mercury in an abandoned van. During the ensuing 25 days, the children shared and played with the mercury outdoors, inside homes, and at local schools. On August 25, 1994, a parent notified local police and fire authorities that her children had brought mercury into the home. On the same day, 50 homes were immediately vacated and an assessment of environmental and health impacts was initiated by the State of Florida Department of Environmental Protection, the Health and Rehabilitative Services of the Palm Beach County Public Health Unit, and the U.S. Environmental Protection Agency. This report summarizes the investigation of this incident.

Door-to-door interviews of the entire neighborhood (n=363) were conducted, and a decontamination facility was established at the civic center. Based on information collected during the initial survey, residential structures and several classrooms at the local high school were tested for the presence of mercury. Ambient air samples (i.e., adult breathing zone grab samples collected approximately 5 feet above the floor) were collected in affected structures during the 6 days following the report of children handling mercury. In addition, during August 25–29, initial blood and urine samples were collected from potentially exposed persons and analyzed for mercury levels.

A total of 58 residential structures were monitored for indoor mercury vapor concentrations; unsafe indoor air levels of mercury (>15 μ g/m³) were detected in 17, prompting the immediate evacuation of 86 persons. Several classrooms at the local high school were determined to be contaminated. This school was closed for 4 days until clearance air sampling indicated that the mercury level was $\leq 10 \mu$ g/m³. This level of mercury was considered safe for students and teachers rotating among the rooms for 50-minute classes. Pregnant women and young children were excluded from entering classrooms until mercury levels decreased to $\leq 0.3 \mu$ g/m³.

A total of 477 persons identified by the survey as potentially exposed were evaluated at the emergency department of the local hospital or the health department clinic for mercury poisoning by testing both blood and urine specimens for total inorganic mercury levels. Elevated blood and/or urine mercury levels were detected in

Mercury Exposure — Continued

54 persons: blood levels ranged from 1.1 μ g/dL to 5.5 μ g/dL (normal: <1 μ g/dL) and urine levels ranged from 21 μ g/L to 66 μ g/L (normal: <20 μ g/L). Ambient air samples ranged from 6.5 μ g/m³ to 300 μ g/m³. Although these 54 persons were asymptomatic, concentrations of mercury detected in their blood and urine were consistent with the levels of mercury detected in their homes.

Homes and classrooms were decontaminated by spreading powdered sulfur absorbent on the floors and vacuuming surfaces with high efficiency particulate-arresting (HEPA) filters. Contaminated items (e.g., carpeting, padding, linoleum, clothing, bedding, vacuum cleaners, furniture, and washing machines) were removed and taken to a hazardous waste facility, and some homes required ventilation for periods up to 3 months. Because of the potential for residential exposure of many children and childbearing-aged women, an air mercury concentration of $\leq 0.3 \ \mu g/m^3$ was established as a threshold at which families would be permitted to return to their homes. Ambient air samples were collected 24 inches above the ground (i.e., a child's breathing zone), under normal living conditions for at least 8 hours.

By December 1, 1994, all displaced families had been permitted to return to their homes, and urine mercury levels of all exposed persons decreased. However, the Palm Beach County Health Department continues to monitor persons with persistently elevated urine mercury levels. This incident is under criminal investigation, and information regarding the source of the mercury has not been released.

Reported by: JM Malecki, MD, Health and Rehabilitative Svcs/Palm Beach County Public Health Unit, R Hopkins, MD, State Epidemiologist, State of Florida Dept of Environmental Protection. U.S. Environmental Protection Agency. Air Pollution and Respiratory Health Br, National Center for Environmental Health, CDC.

Editorial Note: Most poisonings associated with exposure to elemental mercury occur in occupational settings, and reports of nonoccupational elemental mercury vapor poisonings are rare, especially in community-based settings (*1,2*). The exposures described in this report primarily affected homes and schools.

Inorganic mercury is a heavy, silver-white metal that is liquid at room temperature. The vapor pressure of mercury is high compared with other metals, creating the continual hazard of airborne exposure to mercury vapor, which is odorless and colorless. Mercury is absorbed into the blood following inhalation and is then transported to the brain and other areas of the nervous system and to all other tissues. Most elemental mercury is excreted unchanged in feces.

The development of clinical manifestations as the result of inhalation of mercury vapor is related to several factors, including the concentration of vaporized mercury, length of exposure, and individual susceptibility (2,3). Acute exposure to elemental mercury produces symptoms of metallic taste, burning, irritation, salivation, vomiting, diarrhea, upper gastrointestinal tract edema, abdominal pain, and hemorrhage (4). Symptoms of high levels of exposure usually begin abruptly and include fever, chills, malaise, nausea, coughing, shortness of breath, chest pain and tightness; the clinical course may progress to pulmonary edema and death (5). In comparison, chronic inorganic mercury poisoning can result in intention tremor, memory loss, insomnia, depression, irritability, excessive shyness, emotional instability, delirium, and acrodynia and may result in a neurologic syndrome known as "mad hatter syndrome" (2–5).

FIGURE I. Notifiable disease reports, comparison of 4-week totals ending June 10, 1995, with historical data — United States



*The large apparent decrease in the number of reported cases of measles (total) reflects dramatic fluctuations in the historical baseline.

[†]Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

TABLE I. Summary — cases of specified notifiable diseases, United States, cumulative, week ending June 10, 1995 (23rd Week)

	Cum. 1995		Cum. 1995
Anthrax Brucellosis Cholera Congenital rubella syndrome Diphtheria <i>Haemophilus influenzae*</i> Hansen Disease Plague Poliomyelitis, Paralytic	33 7 3 1 577 60 2	Psittacosis Rabies, human Rocky Mountain Spotted Fever Syphilis, congenital, age < 1 year [†] Tetanus Toxic shock syndrome Trichinosis Typhoid fever	27 1 84 - 10 93 20 131

*Of 564 cases of known age, 139 (25%) were reported among children less than 5 years of age. [†]Updated quarterly from reports to the Division of Sexually Transmitted Diseases and HIV Prevention, National œnter for Prevention Services. First quarter data not yet available.

-: no reported cases

Reporting Area	AIDS*	Gono	rrhea		4	E	3	C/N/	A,NB	Legior	nellosis
	Cum. 1995	Cum. 1995	Cum. 1994	Cum. 1995	Cum. 1994	Cum. 1995	Cum. 1994	Cum. 1995	Cum. 1994	Cum. 1995	Cum. 1994
UNITED STATES	29,887	152,685	167,729	10,868	9,685	4,191	5,110	1,893	1,896	568	655
NEW ENGLAND	1,471 26	2,122	3,509 44	104 14	141 12	84 6	183 8	49	68	11	11
N.H.	49	47	33	5	6	11	15	5	5	-	-
Mass.	652	1,220	1,270	43	63	32	5 115	42	46	- 7	5
R.I. Conn.	122 608	229 573	200 1,951	11 28	13 45	8 26	3 37	1	11	1 N	6 N
MID. ATLANTIC	7,605	15,699	18,957	657	671	510	660	165	230	66	77
N.Y. City	3,952	2,612 5,501	4,287 6,997	318	231	155	174	83	98	21	-
N.J. Pa.	1,794 1,023	1,704 5,882	2,357 5,316	92 78	144 73	127 82	178 164	69 12	110 21	14 31	14 44
E.N. CENTRAL	2,492	32,919	33,754	1,395	904	427	521	125	168	156	224
Ind.	544 200	2,894	3,573	63	284 144	56 90	85 93	5	4	33	76 75
III. Mich.	1,105 502	8,963 7 <i>,</i> 885	10,178 6.854	203 175	267 117	86 174	149 157	29 91	45 107	11 18	18 35
Wis.	141	2,286	3,080	78	92	21	37	-	-	15	20
W.N. CENTRAL Minn.	697 148	8,284 1,290	9,366 1,463	648 66	466 83	228	282	45 2	36	56	44
lowa Mo.	40 280	657 4,997	585 4,979	38 439	26 204	19 150	16 207	3 26	7 7	12 31	21 12
N. Dak. S. Dak	2 7	13 78	19 85	14 17	1 15	3 1	-	3 1	1	3	4
Nebr.	61 150	- 1 240	622 1 612	25	74	16	15 16	5	6	7	5
S. ATLANTIC	7,773	45,711	44,216	49 508	472	586	1,008	139	9 251	3 87	2 161
Del. Md	154 1 133	890 5 343	784	7 89	14 75	2 98	7 166	1 5	1 15	- 17	36
D.C.	464	2,046	2,857	4	10	10	16	-	- 17	3	5
va. W. Va.	36	4,701	5,472 313	11	59	29	54 10	23	15	3	4
N.C. S.C.	405 398	10,676 5,358	10,884 5,312	56 20	47 12	137 24	129 17	27 9	27 3	16 17	10 9
Ga. Fla.	935 3.696	7,562 8.841	U 10.196	43 192	23 227	50 196	424 185	11 58	148 25	10 15	73 23
E.S. CENTRAL	961	18,981	19,348	518	210	417	507	549	365	15	49
Ky. Tenn.	116 380	2,000 5,543	1,973 5,905	22 416	91 66	34 329	48 423	8 539	13 344	2 9	5 25
Ala. Miss.	263 202	8,023 3,415	6,986 4,484	51 29	31 22	54	36	2	8	3 1	7 12
W.S. CENTRAL	2,513	14,411	19,429	1,287	1,267	611	551	257	187	7	14
Ark. La.	108 366	1,802 5,215	2,906 5,292	116 42	23 68	21 77	10 77	2 62	3 52	2	4
Okla. Tex.	131 1,908	1,122 6,272	1,885 9,346	265 864	111 1,065	206 307	137 327	178 15	103 29	3 2	8 2
MOUNTAIN	975	3,346	4,219	1,836	1,887	366	271	217	197	103	43
ldaho	8 24	38 55	38 34	30 184	13	9 44	9 42	9 28	4 46	4	- 14
Wyo. Colo.	5 339	23 1,300	36 1,471	70 235	10 220	9 58	11 46	87 32	59 30	3 30	2 8
N. Mex. Ariz	81 268	382 1 253	456 1 304	361 524	495 696	136 61	90 27	28 20	32 8	3 44	1 1
Utah	58 192	83	148	376	183 119	34 15	21 25	5	9	5	3 14
PACIFIC	5,400	11,212	14,931	3,915	3,667	962	1,127	347	394	67	32
Wash. Oreg.	463 184	1,080 202	1,302 354	296 700	507 379	73 39	105 69	102 22	123 18	6	7
Calif. Alaska	4,587 45	9,357	12,573 374	2,824 16	2,658 95	836 5	925 7	213 1	249	56	23
Hawaii	121	238	328	79	28	9	, 21	9	4	5	2
Guam P.R.	- 1,099	31 233	61 220	2 48	7 31	333	3 147	- 197	- 72	-	1 -
V.I. Amer. Samoa	19	4 8	11 15	- 5	1 4	2	4	-	-	-	-
C.N.M.I.	-	13	21	15	3	7	-	-	-	-	-

TABLE II. Cases of selected notifiable diseases, United States, weeks endingJune 10, 1995, and June 11, 1994 (23rd Week)

N: Not notifiable U: Unavailable -: no reported cases C.N.M.I.: Commonwealth of Northern Mariana Islands *Updated monthly to the Division of HIV/AIDS Prevention, National Center for Prevention Services, last update May 25, 1995.

							Measle	es (Rube	eola)					
Reporting Area	Ly Dise	me ease	Mal	aria	Indig	enous	Impo	orted*	То	tal	Mening Infec	gococcal ctions	Mu	mps
	Cum. 1995	Cum. 1994	Cum. 1995	Cum. 1994	1995	Cum. 1995	1995	Cum. 1995	Cum. 1995	Cum. 1994	Cum. 1995	Cum. 1994	Cum. 1995	Cum. 1994
UNITED STATES	1,810	2,260	408	415	8	174	-	8	182	709	1,538	1,480	413	677
NEW ENGLAND	193	237	18	26	-	4	-	-	4	22	77	62	6	11
N.H.	3 11	8	1	3	-	-	-	-	-	4 1	5 15	6	4	3
Vt. Mass	3 43	2 36	- 5	1 11	-	- 2	-	-	- 2	2	6 24	2 26	- 1	-
R.I.	41	24	2	4	-	2	-	-	2	6	-	-	-	1
CONN. MID ATLANTIC	92 1 310	167	9 Q/	62 62	-	-	-	- 2	- 2	3 192	2/ 192	146	58	3 62
Upstate N.Y.	795	1,213	20	19	-	-	-	-	-	14	63	45	15	15
N.Y. City N.J.	29 130	2 166	40 23	17 16	-	1	-	2	3	10 161	19 55	21 35	5 5	11
Pa.	356	127	11	10	-	-	-	-	-	7	55	45	33	36
E.N. CENTRAL Ohio	23 17	183 11	41 3	46 7	-	6 1	-	1	7 1	91 15	195 63	199 54	70 22	123 31
Ind.	3	6	2	8	-	-	-	-	-	1	27	24	1	6
Mich.	2 1	9	25 9	18	-	3	-	- 1	4	54 18	58 40	26	24 23	55 27
Wis.	-	156	2	2	-	2	-	-	2	3	7	23	-	4
W.N. CENTRAL Minn.	21	31	9 3	22 5	-	1	-		1	161	91 16	101 9	27 2	34 3
lowa Mo	1	1	1	4	-	- 1	-	-	- 1	-	16	12	8	9
N. Dak.	-	- 20	-	9	-	-	-	-	-	- 159	1	40	-	2
S. Dak. Nebr	- 1	-	- 2	- 2	-	-	-	-	-	- 1	4	6 8	- 4	- 1
Kans.	15	3	-	1	-	-	-	-	-	1	12	17	-	-
S. ATLANTIC	178 7	220	92 1	87 3	2	3	-	-	3	11	263	222	45	103
Md.	, 121	73	23	39	-	-	-	-	-	2	15	13	-	25
D.C. Va.	- 12	1 22	9 16	8 9	-	-	-	-	-	2	1 31	2 38	13	24
W. Va.	12 14	7	1	- 2	-	-	-	-	-	-	4	9 35	- 16	3 24
S.C.	5	3	-	2	-	-	-	-	-	-	33	11	7	6
Ga. Fla.	5 2	57 4	11 24	12 12	2	- 3	-	-	- 3	2 5	59 72	51 61	- 9	7 14
E.S. CENTRAL	10	17	8	12	-	-	-	-	-	28	92	116	14	13
Ky. Tenn	1	11 5	- 3	4 5	-	-	-	-	-	- 28	29 24	24 22	- 4	- 5
Ala.	1	1	5	2	-	-	-	-	-	-	24	46	4	1
WISS.	2 42	- 35	- 9	14	- 2	- 13	-		- 13	- 12	192	24 177	25	7 148
Ark.	2	1	2	-	-	2	-	-	2	1	19	27	2	4
La. Okla.	1 16	- 19	1	2	2	11	-	-	11	1	28 20	23 18	-	15 21
Tex.	23	15	6	10	-	-	-	-	-	10	125	109	16	108
MOUNTAIN Mont.	3	1	27 2	18	4	46	-	1	47	146	120 2	107 2	26 1	45
Idaho	-	1	1	2	-	-	-	-	-	-	5	13	2	5
Colo.	1	-	15	8	4	7	-	-	7	19	5 27	5 17	1	1
N. Mex. Ariz	-	-	3	2 1	-	28 10	-	-	28 10	-	26 42	11 40	N 5	N 25
Utah	-	-	2	4	-	-	-	1	1	118	6	15	10	7
NEV.	30	- 28	ا 110	1 128	0	ا 100	0	-	1 10/1	9 46	/ 316	4 350	1/12	0 138
Wash.	2	-	11	13	-	13	-	2	15	-	54	53	10	8
Oreg. Calif.	2 26	2 26	4 87	10 97	-	1 86	-	- 1	1 87	44	51 203	76 215	N 119	N 120
Alaska Hawaii	-	-	1	- Q	-	-	-	- 1	- 1	- 2	6	2	9 1	2
Guam	-	-	-	o -	- IJ	-	- U	-	-	∠ 214	2	4	4	о З
P.R.	-	-	1	2	-	9	-	-	9	11	12	5	-	2
v.i. Amer. Samoa	-	-	-	-	U	-	U	-	-	-	-	-	2	2
C.N.M.I.	-	-	-	1	-	-	-	-	-	29	-	-	-	-

TABLE II. (Cont'd.) Cases of selected notifiable diseases, United States, weeks endingJune 10, 1995, and June 11, 1994 (23rd Week)

*For imported measles, cases include only those resulting from importation from other countries.

N: Not notifiable U: Unavailable -: no reported cases

	-			-		-			-			
Reporting Area		Pertussis			Rubella		Sypł (Prima Secon	nilis ary & dary)	Tuberc	ulosis	Rab Anii	ies, mal
	1995	Cum. 1995	Cum. 1994	1995	Cum. 1995	Cum. 1994	Cum. 1995	Cum. 1994	Cum. 1995	Cum. 1994	Cum. 1995	Cum. 1994
UNITED STATES	36	1,290	1,544	9	51	163	6,665	9,478	7,572	9,003	2,827	3,138
NEW ENGLAND	1	157	171	1	7	113	84	98	150	172	752	820
N.H.	-	18	39	-	1	-	2 1	4 1	5	6	- 88	92
Vt. Mass	- 1	3 116	27 89	-	- 2	- 112	32	37	1 81	2 84	104 265	70 314
R.I.	-		3	-	-	1	1	9	18	18	123	5
	-	/	11 292	-	3	-	48 202	4/ 612	45	62 1 722	1/2	339
Upstate N.Y.	-	61	102	2	3	5	24	80	177	227	270	526
N.Y. City N.J.	-	22 2	59 9	-	2	-	208 81	288 101	853 300	1,064 302	- 170	139
Pa.	6	29	113	-	-	-	80	144	281	140	232	90
E.N. CENTRAL	6	132	248	-	-	6	1,146	1,349	770	842	10	17
Ind.	-	8	34	-	-	-	97	106	21	73	-	3
III. Mich.	1 2	28 40	51 23	-	-	1 5	444 130	465 144	439 166	415 204	2 6	3 5
Wis.	-	12	71	-	-	-	72	143	24	24	1	6
W.N. CENTRAL	1	63	59 27	-	-	2	340	558	259	216	131	85
lowa	-	20	6	-	-	-	28	21	33	15	47	35
Mo. N. Dak.	-	5 6	14 3	-	-	2	282	478 1	99 1	110 4	16 16	9 4
S. Dak.	-	7	-	-	-	-	-	-	10	9	22	12
Nebr. Kans.	-	4 11	3	-	-	-	9	30	48	28	26	17
S. ATLANTIC	-	111	163	6	15	10	1,613	2,375	1,404	1,755	950	846
Del. Md.	-	5 14	- 53	-	-	-	7 36	13 99	12 193	14 141	33 202	21 279
D.C.	-	2	3	-	-	-	57	110	44	49	8	2
W. Va.	-	o -	2	-	-	-	295	306	45	40	43	34
N.C. S.C.	-	50 11	44 10	-	-	-	518 292	783 308	130 138	212 185	189 59	84 80
Ga.	-	1	11	-	-	-	234	381	260	332	136	168
	-	20	25	ю	15	10	1/3	307	477	626	103	3
Ky.	-	-	52	-	-	-	93	100	53	141	8	5
Tenn. Ala	-3	4 23	16 14	-	-	-	350 282	428 319	162 172	184 191	11 60	34 55
Miss.	-	-	8	-	-	-	1,093	815	65	110	-	-
W.S. CENTRAL	-	61	40	-	2	7	966 182	2,206	983	986	52	330
La.	-	4	о 5	-	-	-	486	831		7	23	41
Okla. Tex	-	13 44	20 7	-	- 2	4	35 263	71 1.073	96 812	108 782	18	17 258
MOUNTAIN	15	438	176	-	4	3	102	143	247	206	54	56
Mont.	- 2	3 74	3	-	-	-	3	1	3	9	20	7
Wyo.	1	1	-	-	-	-	2	-	1	2	16	10
Colo. N. Mex.	6 1	12 30	93 9	-	-	-	65 5	74 6	4 40	20 27	- 3	1 2
Ariz.	5	303	34	-	3	-	17	33	134	92	13	34
Nev.	Ū	10	12	Ū	-	2	3 7	21	49	50	1	2
PACIFIC	4	187	314	-	18	17	203	474	1,696	2,467	127	135
Wash. Oreg.	1	34 7	41 41	-	1	-	7	20 17	121 23	105 54	-	-
Calif.	3	130	226	-	15	15	189	434	1,446	2,164	123	104
Alaska Hawaii	-	16	6	-	- 1	2	1 -	2	35 71	30 114	4	31
Guam	U	-	1	U	-	1	1	3	4	23	-	-
P.R. V.L	-	6	2	-	-	-	135 1	149 22	56	62	18 -	41
Amer. Samoa	Ŭ	-	1	Ŭ	-	-	-	1	3	3	-	-
C.IN.IVI.I.	-	-	-	-	-	-	3	-	13	9	-	-

TABLE II. (Cont'd.) Cases of selected notifiable diseases, United States, weeks endingJune 10, 1995, and June 11, 1994 (23rd Week)

U: Unavailable -: no reported cases

	A	II Cau	ses, By	By Age (Years)			P&I [†]		Å	All Cau	ises, B	y Age (Y	(ears)		P&I [†]
Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total	Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total
NEW ENGLAND Boston, Mass. Bridgeport, Conn. Cambridge, Mass. Fall River, Mass. Hartford, Conn. Lowell, Mass. Lynn, Mass. New Bedford, Mass. New Haven, Conn. Providence, R.I. Somerville, Mass. Springfield, Mass.	582 144 35 16 30 82 20 9 53 43 53 43 8 40 26	392 77 25 13 23 48 16 8 15 38 30 7 25 20	101 30 5 2 21 2 12 7 12 7 10 3	56 19 5 11 2 1 2 3 - 1 2	17 10 - - - 2 - 4 1	16 8 - 2 - 1 1 - -	45 6 2 3 - 2 - 1 1 7 4 - 6 1	S. ATLANTIC Atlanta, Ga. Baltimore, Md. Charlotte, N.C. Jacksonville, Fla. Miami, Fla. Norfolk, Va. Richmond, Va. Savannah, Ga. St. Petersburg, Fla. Tampa, Fla. Washington, D.C. Wilmington, Del.	1,326 154 174 84 115 122 81 60 51 61 214 202 8	813 90 108 57 75 64 53 39 37 44 140 102 4	272 28 33 15 23 27 18 14 8 46 54 2	173 26 27 8 13 25 5 4 5 9 21 29 21 29	41 55 232 2 1 3 6 10 1	27 5 1 2 1 4 3 2 - 1 1 7 -	68 2 22 4 5 2 4 1 8 1 7 2 -
Worcester, Mass. MID. ATLANTIC Albany, N.Y. Allentown, Pa. Buffalo, N.Y. Camden, N.J. Elizabeth, N.J. Erie, Pa.§	58 2,385 48 25 102 32 22 46 41	47 1,510 34 15 78 20 11 33	3 478 9 5 12 4 5 10	4 304 2 4 10 5 6	- 62 3 1 2 - 2	4 31 - 1 1 1	12 104 - - 3 3 -	E.S. CENTRAL Birmingham, Ala. Chattanooga, Tenn. Knoxville, Tenn. Lexington, Ky. Memphis, Tenn. Mobile, Ala. Montgomery, Ala. Nashville, Tenn.	730 115 99 58 45 115 71 72 155	480 73 74 38 26 74 53 49 93	140 23 19 11 14 22 8 11 32	79 11 5 6 5 15 9 23	18 3 - 2 2 3 5	12 4 1 - 2 3 - 2	58 6 5 11 2 14 11
New York, N.J. Newark, N.J. Paterson, N.J. Philadelphia, Pa. Pittsburgh, Pa.§ Reading, Pa. Rochester, N.Y. Schenectady, N.Y. Scranton, Pa.§ Syracuse, N.Y. Trenton, N.J. Utica, N.Y. Yonkers, N.Y.	41 1,280 68 26 301 56 14 130 19 28 99 32 32 16 U	778 26 14 187 40 12 104 13 23 70 19 15 U	6 279 22 6 57 12 2 15 5 4 18 6 1 0	15 181 17 6 37 1 - 7 - 1 5 7 - U	1 29 1 14 3 - 2 1 - 2 - 2 - U	13 2 6 - 2 - 4 - U	28 3 2 26 6 - 13 - 2 11 3 - U	W.S. CENTRAL Austin, Tex. Baton Rouge, La. Corpus Christi, Tex. Dallas, Tex. El Paso, Tex. Houston, Tex. Houston, Tex. Little Rock, Ark. New Orleans, La. San Antonio, Tex. Shreveport, La. Tulsa, Okla.	1,436 58 37 215 48 115 339 72 141 195 69 110	909 39 28 26 128 30 73 215 35 91 126 44 74	287 6 5 7 52 13 22 61 19 22 44 14 22	145 11 3 22 3 8 42 7 19 16 5 8	58 - 8 2 6 14 9 6 5 4 4	37 2 3 1 5 - 6 7 2 3 4 2 2	88 4 3 2 4 5 29 9 - 19 6 7
E.N. CENTRAL Akron, Ohio Canton, Ohio Cincinnati, Ohio Cleveland, Ohio Columbus, Ohio Dayton, Ohio Detroit, Mich. Evansville, Ind. Fort Wayne, Ind. Grand Rapids, Mich Indianapolis, Ind. Madison, Wis. Milwaukee, Wis. Peoria, III. Rockford, III. South Bend, Ind. Toledo, Ohio Youngstown, Ohio	2,193 588 32 449 133 156 190 119 241 399 241 139 72 24 41 109 388 45 43 97 87 716	1,494 466 285 104 101 132 87 132 300 50 14 36 121 22 766 226 32 32 36 525	388 392 185 399 200 49 4 328 11 247 7 3 186 320 49 4 328 11 247 7 3 186 32 320 49 4 328 329 200 49 4 328 329 200 49 4 328 329 200 49 40 328 329 200 49 40 328 329 200 49 40 328 329 200 49 40 328 329 200 49 40 329 200 49 40 328 329 200 49 40 328 329 200 49 40 328 329 200 49 40 328 329 200 49 40 328 329 200 49 40 328 329 200 40 328 329 200 40 328 329 200 40 329 200 40 328 329 200 40 328 329 200 40 328 329 200 40 40 328 329 200 40 329 200 40 329 329 40 329 329 329 329 329 329 329 329 329 329	187 151 161 136 286 1135 424 353 53	63 	612201104262 10104262 332422114	139 439 172 18 10 52 4 9 4 46 1 52 43 50	MOUNTAIN Albuquerque, N.M. Colo. Springs, Colo Denver, Colo. Las Vegas, Nev. Ogden, Utah Phoenix, Ariz. Pueblo, Colo. Salt Lake City, Utah Tucson, Ariz. PACIFIC Berkeley, Calif. Fresno, Calif. Glendale, Calif. Honolulu, Hawaii Long Beach, Calif. Portland, Oreg. Sacramento, Calif. San Diego, Calif.	950 108 52 136 171 27 176 21 99 160 2,126 14 88 31 89 81 531 23 190 199 199 173	627 69 37 77 111 20 96 20 700 127 1,443 11 57 25 61 54 352 18 137 145 112 95	167 29 40 31 15 19 344 21 2 4 17 97 329 322 320	97 14 3 21 13 2 26 9 9 9 231 1 12 1 8 5 68 2 10 17 26 29	31 3 2 14 - 2 3 51 - 3 - 1 41 - 11 3 3 3	281364'9'32 30'4'212'3242	56 3 4 6 1 15 - 13 10 150 - 9 3 7 4 29 4 10 19 24 8
Des Moines, Iowa Duluth, Minn. Kansas City, Kans. Kansas City, Mo. Lincoln, Nebr. Minneapolis, Minn.	85 26 U 95 35 205	69 21 U 53 27 150	93 8 2 U 18 4 29	3 2 U 10 4 13	2 - U 1 - 8	3 1 U 3 - 5	9 5 U 7 12	San Jose, Calif. Santa Cruz, Calif. Seattle, Wash. Spokane, Wash. Tacoma, Wash. TOTAI	184 30 139 69 106 12 444 [¶]	124 21 100 53 78 8,193	34 21 8 11 2.270	18 3 12 5 14 1.324	5 1 2 2 2 359	3 1 4 1 1 260	19 1 8 3 2 758
Omaha, Nebr. St. Louis, Mo. St. Paul, Minn. Wichita, Kans.	89 119 62 U	70 93 42 U	8 12 12 U	6 8 6 U	3 3 1 U	2 3 1 U	6 5 5 U		12,774	5,100	2,2,0	1,027	000	200	, 50

TABLE III. Deaths in 121 U.S. cities,* week ending June 10, 1995 (23rd Week)

*Mortality data in this table are voluntarily reported from 121 cities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.
¹Pneumonia and influenza.
⁸Because of changes in reporting methods in these 3 Pennsylvania cities, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.
¹Total includes unknown ages.
U: Unavailable -: no reported cases

Vol. 44 / No. 23

MMWR

Mercury Exposure — Continued

The risks associated with mercury exposure are especially increased for children because mercury vapor is dense and settles (2) and because children may be active on the floor or playing in dirt. In addition, because of lipid solubility, mercury crosses the placenta and is excreted in breast milk and, therefore, is a potential health hazard for unborn children and breastfeeding infants (6,7).

Elemental mercury is still widely used in industry for the manufacture of thermometers, barometers, vacuum pumps, and electrical components and may be present in household products such as cleaning solutions and adhesives (2,5). Small amounts of mercury, such as from a broken thermometer, can be cleaned up by spraying the mercury gently with hairspray or dusting with an absorbent such as powdered sulfur and sweeping up the mercury and absorbent with a wisk broom. After cleaning the spill, the broom should be securely bagged and discarded (8). Any person who discovers a large quantity of mercury should immediately contact the local poisoncontrol center or health department.

The residential exposure described in this report was unprecedented in terms of the amount of mercury involved and the extent of contamination. The rapid and coordinated response to this incident minimized the risk for and assured the health of the exposed residents.

References

- 1. CDC. Elemental mercury vapor poisoning—North Carolina, 1988. MMWR 1989;38:770-2,777.
- 2. CDC. Elemental mercury poisoning in a household—Ohio, 1989. MMWR 1990;39:424-5.
- 3. Knight, AL. Mercury and its compounds. In: Zenz C, ed. Occupation medicine: principles and practices. 2nd ed. Chicago: Year Book Medical Publishers, 1988:590–6.
- 4. Rumack B, Peterson R. Clinical toxicology. In: Doull J, Klassen C, Amdu M, eds. Toxicology: the basic science of poisons. 2nd ed. New York: Macmillan Publishing Co., Inc., 1980:690–1.
- 5. Taueg C, Sanfilippo DJ, Rowens B, Szejda J, Hesse JL. Acute and chronic poisoning from residential exposures to elemental mercury—Michigan, 1989–1990. Clin Toxicol 1992;30:63–7.
- 6. Sikorski R, Juszkiewicz T, Paszkowski T, Szprengier-Juskiewicz T. Women in dental surgeries: reproductive hazards in occupational exposure to metallic mercury. Archives Occupational Environmental Health 1987;59:551–7.
- 7. Thorp JM, Boyette DD, Watson WL, Cefalo RC. Elemental mercury exposure in early pregnancy. Obstet Gynecol 1992;79:874–6.
- 8. Micromedics, Inc. Poisindex [Software]. Denver: Micromedics, Inc., 1995 (Vol 85).

Unexplained Illness Among Persian Gulf War Veterans in an Air National Guard Unit: Preliminary Report — August 1990–March 1995

In November 1994, the U.S. Department of Veterans' Affairs (VA), the Department of Defense (DoD), and the Pennsylvania Department of Health requested that CDC investigate a report of unexplained illnesses among members of an Air National Guard (ANG) unit in south-central Pennsylvania (Unit A) who were veterans of the Persian Gulf War (PGW) (August 1990–June 1991). These veterans had been evaluated at a local VA medical center for symptoms that included recurrent rash, diarrhea, and fatigue. A three-stage investigation was planned to 1) verify and characterize signs and symptoms in PGW veterans attending the VA medical center; 2) determine

Unexplained Illness — Continued

whether the prevalence of symptoms was higher among members of Unit A than among members of other units deployed to the PGW and, if so, whether the increased prevalence was associated with PGW deployment; and 3) characterize the illness and identify associated risk factors. This report presents preliminary findings from stages 1 and 2 (stage 3 is in progress).

Stage 1

In December 1994, a team of CDC medical epidemiologists visited the VA medical center, conducted standardized interviews and performed standardized physical examinations of 59 PGW veterans reported to be symptomatic, and reviewed medical records. Of the 59 veterans, 26 were selected from the health registry that had been established for PGW veterans who reported symptoms believed to be related to service in the Persian Gulf, and 14 were selected as typical cases by the physician who reported the illnesses to VA; the remaining 19 were listed on the registry but had not yet been evaluated at the VA medical center to determine whether they were eligible to be on the registry. In addition, 40 primary-care physicians and 16 regional hospitals in south-central Pennsylvania were surveyed; the survey did not identify additional PGW veterans with any health complaints.

The median age of the 59 persons was 39 years (range: 23–59 years), and 53 (90%) were male. All were enlisted personnel: 30 (51%) had been assigned to Unit A during the PGW and the remainder were in other Air Force units and military branches; 48 (81%) had been in the military for \geq 10 years; 16 (27%) had served \geq 5 years on active duty; and 19 (32%) had been deployed for \geq 2 tours to the PGW theater. At the time of the survey, 89% were employed in addition to their ANG work.

The most frequently reported symptoms considered "moderate" or "severe" were fatigue (61%), joint pain (51%), nasal or sinus congestion (51%), diarrhea (44%), joint stiffness (44%), unrefreshing sleep (42%), excessive gas (i.e., flatulence, bloating, and gastrointestinal distress) (41%), "difficulty remembering" (41%), muscle pains (41%), headaches (39%), abdominal pain (36%), general weakness (34%), and impaired concentration (34%). The two symptoms identified as "most bothersome" were fatigue (27%) and diarrhea (14%). Patients reported that their symptoms began during or 2–3 months after departure from the Persian Gulf, and all reported that several symptoms persisted \geq 6 months. No consistent abnormalities were identified among the participants on standardized physical examination or by review of medical records and accompanying laboratory tests performed at the VA medical center. After the war, one participant had viscerotropic leishmaniasis diagnosed and treated.

Stage 2

From January through March 1995, members of Unit A and three comparison units (units B, C, and D) were surveyed to determine the prevalence of selected symptoms identified in stage 1 and to examine the relation between reported symptoms and PGW service. Comparison units were chosen for similarity in mission responsibility to Unit A and were located in Pennsylvania and another state. Units B and C (both reserve units) were surveyed during routine monthly training sessions, and Unit D (an active duty unit) was surveyed immediately after the Unit C survey. All personnel on each base at the time of the survey were asked to participate, regardless of health status or participation in the PGW, by anonymously completing a questionnaire describing the frequency, duration, and severity of 35 symptoms most commonly

Unexplained Illness — Continued

mentioned during the stage 1 investigation and a general health history. In addition, personnel who had been deployed to the Persian Gulf were asked about possible exposures (e.g., geography [location of service], duties [combat or support], medical and other procedures [e.g., vaccinations, dental work], outdoor activities [sports, recreation, mission-related], and food and water sources).

A total of 3927 personnel participated in the survey. Response rates varied by unit: 63% (677 of 1083) in Unit A, 36% (540 of 1520) in Unit B, 74% (843 of 1141) in Unit C, and 78% (1867 of 2407) in Unit D. The distribution of demographic characteristics and deployment status of the study participants was similar to the distribution of these variables in the population of each unit.

In all units, the prevalence of each of 13 chronic (lasting≥6 months) symptoms was significantly greater (p<0.05) among persons deployed to the PGW than among those not deployed (Table 1). The prevalences of five symptom categories—chronic diarrhea, other gastrointestinal complaints (gas, bloating, cramps, or abdominal pain), difficulty remembering or concentrating, "trouble finding words," and fatigue—were significantly greater (p<0.03) among deployed personnel from Unit A than among deployed personnel from each of the other units. Symptom prevalences among non-deployed personnel were similar in all units.

Reported by: KW Kizer, MD, Dept of Veterans' Affairs. S Joseph, MD, Dept of Defense. M Moll, MD, JT Rankin, DVM, State Epidemiologist, Pennsylvania Dept of Health. Div of Viral and Rickettsial Diseases, National Center for Infectious Diseases; National Center for Environmental Health, CDC.

Editorial Note: Approximately 700,000 U.S. troops (active duty, reserve, and National Guard) were deployed to the Persian Gulf region during operations Desert Shield and Desert Storm from August 1990 through June 1991. Previous assessments of the health status of PGW veterans have been based on analysis of health registries established by VA and DoD to rapidly identify and report illnesses among PGW veterans (*1*). Through March 1995, approximately 43,000 and 16,000 PGW veterans had enrolled in the VA and the DoD registries, respectively. Efforts have not identified a specific etiology or biologic explanation for these illnesses, nor have specific diseases or syndromes been identified.

The preliminary findings of this investigation are subject to at least two limitations. First, the stage 2 data on symptom prevalence reflect self-reported information that was not evaluated by physical examination and laboratory tests. However, standardized physical examinations and review of VA laboratory test results from patients in stage 1 did not reveal consistent abnormalities. Second, participation rates for the stage 2 survey varied widely; because persons with symptoms may have been more likely to participate, the prevalence of reported health conditions may have been overestimated.

The preliminary findings presented in this report indicate that some chronic symptoms were reported more commonly by PGW veterans than by nondeployed PGW-era service personnel. Potential explanations for the higher prevalence of symptoms among deployed personnel—and the increased prevalence among deployed personnel from Unit A—may include factors specific to the Persian Gulf region (e.g., environmental, toxic, and infectious exposures); factors related to military service and combat (e.g., exposure to toxic agents and combat-related stress); characteristics associated with the general population (e.g., stress-related disorders, age-related

		Unit A			Unit B			Unit C		Unit D			
Symptom	Deployed (n=313)	Not deployed (n=364)	PR§	Deployed (n=119)	Not deployed (n=421)	PR	Deployed (n=262)	Not deployed (n=581)	PR	Deployed (n=470)	Not deployed (n=1397)	PR	
Diarrhea [¶]	27%	2%	12.5	15%	3%	5.3	10%	3%	3.6	13%	3%	4.1	
Memory ^{¶**}	46%	9%	5.2	23%	5%	4.5	26%	8%	3.4	28%	8%	3.6	
Rash	25%	5%	5.3	15%	3%	4.5	20%	6%	3.7	19%	4%	4.4	
"Trouble finding													
words"¶	31%	9%	3.5	10%	5%	2.2	22%	8%	2.7	24%	8%	3.1	
Joint pain	38%	10%	4.0	35%	9%	4.1	29%	13%	2.2	30%	10%	3.0	
Fatique¶	54%	16%	3.4	42%	12%	3.4	36%	14%	2.7	33%	12%	2.9	
Joint stiffness	33%	11%	3.0	26%	6%	4.4	26%	11%	2.4	26%	8%	3.4	
Irritability or													
moodiness	29%	10%	2.9	20%	4%	5.3	24%	7%	3.4	23%	7%	3.3	
Depression	25%	9%	2.8	13%	6%	2.4	13%	8%	1.6	13%	8%	1.8	
Gastrointestinal ^{¶,††}	38%	14%	2.7	18%	11%	1.7	18%	10%	1.9	20%	10%	2.0	
Unrefreshing sleep	29%	12%	2.5	29%	6%	4.6	23%	10%	2.3	22%	9%	2.5	
Sinus congestion	51%	31%	1.6	45%	29%	1.6	44%	38%	1.2	44%	27%	1.6	
Headache	43%	32%	1.4	41%	30%	1.4	42%	32%	1.3	46%	29%	1.6	

TABLE 1. Prevalence rates and ratios* for 13 chronic (i.e., ≥6 months' duration) symptoms reported by ≥25% of sur	veyed
personnel in Unit A who were deployed to the Persian Gulf War theater, by unit [†] — January–March, 1995	

*All prevalence ratios were significant at p<0.05 except for sinus congestion in unit C. [†]Comparison units were chosen for similarity in mission responsibility to Unit A; units B and C were reserve units, and Unit D was ¹ Significantly greater (p≤0.03) among deployed personnel from unit A than among deployed personnel from all of the other units.
¹ Gas, bloating, cramps, or abdominal pain.

446

Vol. 44 / No. 23

MMWR

Unexplained Illness — Continued

effects, or other poorly defined chronic illnesses); and factors especially specific to Unit A (e.g., increased local concern and media attention about illnesses related to PGW service when compared with other units). The stage 3 case-control study, which is in progress, will assess risk factors in ill and healthy PGW veterans from Unit A.

Mechanisms have been established to rapidly identify and treat PGW veterans with health problems. All PGW veterans with health problems are encouraged to obtain an evaluation at their local VA medical center or military treatment facility. Veterans can be referred for further evaluation at specialized referral centers established by VA and DoD.

PGW veterans and their eligible family members can register for medical examination and treatment by calling toll-free telephone numbers (VA: [800] 749-9387; DoD: [800] 796-9699). DoD has established a separate toll-free number ([800] 472-6719) for PGW veterans to report details of incidents they believe may be associated with a medical problem experienced since returning from the Persian Gulf and for healthcare providers with questions about illnesses possibly related to service in the PGW.

Reference

 Institute of Medicine. Health consequences of service during the Persian Gulf War: initial findings and recommendations for immediate action. Washington, DC: National Academy Press, 1995.

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to *lists@list.cdc.gov*. The body content should read *subscribe mmwr-toc*. Electronic copy also is available from CDC's World-Wide Web server at http://www.cdc.gov/ or from CDC's file transfer protocol server at *ftp.cdc.gov*. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 783-3238.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to: Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (404) 332-4555.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Director, Centers for Disease Control and Prevention	Editor, <i>MMWR</i> Series Richard A. Goodman, M.D., M.P.H.						
David Satcher, M.D., Ph.D.	Managing Editor, MMWR (weekly)						
Deputy Director, Centers for Disease Control	Karen L. Foster, M.A.						
and Prevention	Writers-Editors, MMWR (weekly)						
Claire V. Broome, M.D.	David C. Johnson						
Director, Epidemiology Program Office	Darlene D. Rumph-Person						
Stephen B. Thacker, M.D., M.Sc. Caran R. Wilbanks							
☆U.S. Government Printing Office: 1995-633-175/05078 Region IV							